
Maître Philippe MALHERBE
Avocat (Liedekerke)
Maître de conférences à l’UCL
Concept?
Hoping to stimulate innovation (or seeming to do so) the law grants a tax deduction of 80% on income from new patents. The texts are found in articles 205/1 to 205/4 of the Income Tax Code.
Who can benefit?
The 80% deduction is open to every Belgian company and every Belgian establishment of a foreign company, whatever its sector of activity, even if the initial application was from the pharmaceutical industry.
For what patents?
Income from patents or additional protection certificates which make it possible, for drugs and for phytopharmaceutical products, to extend the protection, which otherwise would not exist, without purpose, have the right to the deduction only during the period required to obtain the marketing authorisations. We are talking about patents, while observing – and deploring – that the Belgian law does not cover other intellectual rights.
The right to the deduction extends to patents belonging, possibly in joint ownership, to the company that has developed them totally or partially in a Belgian or foreign research centre. It also extends to rights acquired or licensed from third parties, but improved in such a centre.
The law demands that the research centre constitutes a branch of activity, which would appear to mean a centre equipped with a certain level of autonomy, and not the traditional “garage”, and in any case excludes development entrusted entirely to third parties. This requirement seems disproportionate, even discriminatory, in relation to a legitimate desire to avoid abuse.
Only new patents are eligible, defined as those that have not been used before 1st January 2007 for the marketing of goods and services on the market.
For what income?
The deduction will benefit the licence income, but not the selling price: it is therefore better to lease than to sell. It does not benefit the share of income corresponding to other things than the patents. It also benefits from the share of the sales price of goods or services produced or provided by means of the patent, which corresponds to the fee that a third party pays to have the right to produce or provide them himself; an early decision would be useful in determining this theoretical share.
Eliminating abuse: in the event of special relations, the eligible income is limited to the “arm’s-length” amount, to the full amount. In any case it is limited to their net amount after deducting the correlative charges, namely the amortisation of the purchase price (but not the cost of development) or the licensing fee. Be aware that neither eligible income nor the cost of fees to be excluded include the “contributions to the real costs of research and development that are borne”, according to the case, by the company or by the third party.
What deduction?
The deduction is equal to 80% of eligible income, which is then taxed at 33.99% *20% = 6.8%. If the income has been taxed abroad, this rate will also be the threshold for imputation of any fixed share of foreign tax. Technically, the deduction is made after the deduction of dividends received and before the deduction of notional interest or losses, which is fortunate because excesses cannot be deferred.
Simple example. A company has developed internally a patent, which it is licensing to a third party:
Income from patents: 100
Deduction for patent income (80)
Tax base: 20
Corporate Tax (33.99%) (6.8)
Net income after tax (100 – 6.8) = 93.2
Conclusion.
This relatively simple and clear measure is part of quite a nice legislative arsenal 1, assuring a certain attraction to Belgium for multinational companies.